新型コロナウイルス感染症 (COVID-19) が蔓延しておりますが、我々Selleckは従業員とビジネスパートナーの安全を保つための複数の対策を実施し、お客様に製品を継続してお届けします。
COVID-19関連製品はこちら

Temozolomide (CCRG 81045)

製品コード：S1237 別名：NSC 362856,TMZ

For research use only.

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

CAS No. 85622-93-1

サイズ	価格(税別)
10mM (1mL in DMSO)	JPY 13300
25mg	JPY 13600
100mg	JPY 30200
1g	JPY 146400

代表番号: 03-5615-9297\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（150）

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

相関DNA/RNA Synthesis製品

Blasticidin S HCl

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
Cisplatin (NSC 119875)

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.
Gemcitabine (LY-188011) HCl

Gemcitabine (LY-188011, NSC 613327) HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.
Oxaliplatin (NSC 266046)

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin (NSC125066) sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine (LY-188011)

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.

Download Inhibitor Catalog

DNA/RNA Synthesis Signaling Pathway Map

生物活性

製品説明

特性

Methazolastone is a second-generation alkylating agent.

ターゲット

DNA replication ^[1]
(L-1210, L-1210/BCNU cells)

体外試験

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.^[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. ^[2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. ^[3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. ^[4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. ^[5]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Kelly	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXK0PEBp		NUj4TlVjUUN3ME2xN\|kvOjEkgJpCtgKBkTVwOUWg{txO	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
KellyCis83	M3LCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1HDVVQ5KGh?		NYnGeJRJUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
SK-N-AS	NXjURXNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M336flQ5KGh?		NGTZT5lKSzVyPUKyO{44OOLCidMx5qCKOjJwMUWg{txO	MmXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
SK-N-ASCis24	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFP6b401QCCq		MWDJR\|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=>	M3fHW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
CHP-212	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NG\TflQ1QCCq		NHrKWpFKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN	NFG2Vno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFI5Oid-MkW5OlAzQDJ:L3G+
CHP-212Cis100	NWTQd3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{SwWVQ5KGh?		NYnqfmhJUUN3ME25MlU26oDLwsJihKkxNjh6IN88US=>	NXnu[45pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
U87	MlXiSpVv[3Srb36gRZN{[Xl?	NUnGNXpsOTByIN88US=>	NUfrU3B3OjRvN{KgbC=>		M1\HO4lv\HWlZYOgSINTOSCneIDy[ZN{cW:w	M3i4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC4PFY5Lz5{NUiwPFg3QDxxYU6=
LN229	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3ENE02OCEQvF2=			NFK4NotKSzVyPUG2JO69VQ>?	MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUCyO\|MoRjJ3N{WwNlc{RC:jPh?=
TR-LN229	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUewMVUxKM7:TR?=			NWnZNnNxUUN3ME23O{DPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEK3N{c,OjV5NUCyO\|M9N2F-
U87	NWi5OXNQSXCxcITvd4l{KEG\|c3H5	M1n4U\|DjiJN{MEFihKnDvU1?	NVLFTndkOjRiaB?=		MoDu[Y5p[W6lZYOgR3EhcW6mdXPl[EBieG:ydH;zbZM>	Ml7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OEG2OlgoRjJ3NkixOlY5RC:jPh?=
U251MG	MnLiRZBweHSxc3nzJGF{e2G7	NIjiNogyODEEoN88US=>	NFu0eoQ1QCCq	MXvQRnM>	MoDObY5lfWOnczDhdI9xfG:\|aYO=	M2jNT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkiwOFY1Lz5{NU[4NFQ3PDxxYU6=
U87MG	MYnBdI9xfG:\|aYOgRZN{[Xl?	MV:xNFDDqM7:TR?=	M4\5[lQ5KGh?	Ml3PVGJU	Mkn2bY5lfWOnczDhdI9xfG:\|aYO=	NIW3[IM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87	NVLNXWNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlThOVAuOzVyIN88US=>	NX;1b3pIPDkEoHlCpC=>		MoXXbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk>	Mnq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U118	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWi1NE0{PTBizszN	MV60POKhcMLi		NX7HdHpkcW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl?	M2jXeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
U87	MmrYSpVv[3Srb36gRZN{[Xl?	MUCyOVAwOzVyIN88US=>	MlS1OFjDqGkEoB?=		MYXlcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U>	NHrkb\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U118	NVH3cVVLTnWwY4Tpc44hSXO\|YYm=	NFPY[IMzPTBxM{WwJO69VQ>?	MYe0POKhcMLi		NV\tOVds\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn	MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U87	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfhNlUxNzN3MDFOwG0>	M2jaTlQ5yqCqwrC=		M1mwS4lv[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBUKGGwZDDHNk9OyqClb4Ty[YF1\WRid3n0bEBVVVh?	MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
A375	Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVq0POKhcMLi		MnH1TWM2OD1{NkWg{txO	NVvRclJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlQ2PTJpPkK1OVI1PTV{PD;hQi=>
A2058	NYS1XFlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXH4UndYPDkEoHlCpC=>		NV7EbFhWUUN3ME2xNkDPxE1?	NWDabVYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlQ2PTJpPkK1OVI1PTV{PD;hQi=>
M238	NFnTbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFjYcXE1QMLiaNMg		NYW5TY8{UUN3ME20NEDPxE1?	M324TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK0OVUzLz5{NUWyOFU2OjxxYU6=
M249	M4TXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFfRemM1QMLiaNMg		MULJR\|UxRTJ3NDFOwG0>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
M21	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1;weFQ5yqCqwrC=		NV\ZOm5uUUN3ME2yNlEh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
U251	NHflZldEgXSxdH;4bZR6KEG\|c3H5	NETwVGYzOCEQvF5CpC=>	Mn:5OFjDqGkEoB?=		NF3DdI1z\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk	M{f1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO0N\|gyLz5{NUSzOFM5OTxxYU6=
LN229	M4j0eWN6fG:2b4jpeJkhSXO\|YYm=	MXqyNEDPxE4EoB?=	M{Lhb\|Q5yqCqwrC=		NVjXUpVwemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|NEO4NUc,OjV2M{SzPFE9N2F-
U373MG-LUC	M2K5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGLXUZA4OiCq		M3i5TWlEPTB-NkCwJO69VQ>?	M4DWO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxPVU{Lz5{NUSzNVk2OzxxYU6=
U87	NFTpS\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWCyOU0zODBizszN	NXT5OYFFPDkEoHlCpC=>		NFj3UlVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NGDWSXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwNFc1PSd-MkW0NFA4PDV:L3G+
U251	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlT4NlUuOjByIN88US=>	NFn5fVE1QMLiaNMg		MlKwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MorjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEC3OFUoRjJ3NECwO\|Q2RC:jPh?=
U251	M{\FcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlX3NVAxNTRyMDFOwG0>	M3H5cVczNzl4IHi=		M37Le5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5NUK3NUc,OjV\|N{WyO\|E9N2F-
U373	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNFAuPDByIN88US=>	NYHPXHVuPzJxOU[gbC=>		NXXlcVA1fGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg	NX3UNFdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|UzPzFpPkK1N\|c2OjdzPD;hQi=>
U343	M2PlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPkUJBLOTByLUSwNEDPxE1?	NGLnXXE4Oi97NjDo		MWD0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5NUK3NUc,OjV\|N{WyO\|E9N2F-
U87MG-luc2	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXLPHJFOTByLUSwNEDPxE1?	NH7Fc2Q4Oi97NjDo		NW\BSoJofGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg	NULmfHZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|UzPzFpPkK1N\|c2OjdzPD;hQi=>
U87	NFXLPGdHfW6ldHnvckBCe3OjeR?=	MX:yNFAh\|ryP	NXrBVoZIPDhiaB?=		M1;lNYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25?	NEfs[Gk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
U251	M3ewXmZ2dmO2aX;uJGF{e2G7	MknDNlAxKM7:TR?=	M3nISlQ5KGh?		MlK3bY5kemWjc3XzJGJTS0N\|IH3SUmEh\XiycnXzd4lwdg>?	MknjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
A172	MoXiSpVv[3Srb36gRZN{[Xl?	NXHDUXY2OjByIN88US=>	NWT5UWhbPDhiaB?=		M1f0[4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN\|N{eyNUc,OjV\|M{e3NlE9N2F-
U251	M4O5TmZ2dmO2aX;uJGF{e2G7	M2DBUVIxOCEQvF2=	M4q0T\|Q5KGh?		M2H0bolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN\|N{eyNUc,OjV\|M{e3NlE9N2F-
A172	NXy2V5E{TnWwY4Tpc44hSXO\|YYm=	M3zj[FIxOCEQvF2=	Ml;lOFghcA>?		NHnvSWdqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{	NVHid2tJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U87	MmnQSpVv[3Srb36gRZN{[Xl?	NIDsTJczODBizszN	MlH4NlQwPzJxMUKwJIg>		NUnXUHFRcW6lcnXhd4V{KM7\|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7	MofyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
U251	NILF[nRHfW6ldHnvckBCe3OjeR?=	NWfTT4hZOjByIN88US=>	MWGyOE84Oi9zMkCgbC=>		M3XwXolv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>?	NEDwdZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
A172	M3nmU2Z2dmO2aX;uJGF{e2G7	NWLCWWExOjByIN88US=>	M1HqbFI1Nzd{L{GyNEBp		NGHHXGVqdmO{ZXHz[ZMh\|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl?	NGC3bXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
SNB19V	M2TLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvkO{Bl	M4rLSGROW09?	NIjmWY5IUTVyPUO1MlfDuTF{IN88US=>	NIrne5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
SNB19M	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFzXfWw4KGR?	NI\MTGNFVVOR	NFn0RohIUTVyPUS2PU46yrF6ODFOwG0>	MlrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19VR	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV63JIQ>	M3nDXGROW09?	MofCS2k2OD1{OECuNuKyOThizszN	MljjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U373V	NIPh[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1j6ZVch\A>?	NX7LR\|QzTE2VTx?=	Ml;PS2k2OD14OD6wxtE{OiEQvF2=	M2P4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373M	NHTxWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUfKd\|VNPyCm	MWDEUXNQ	MXTHTVUxRTN4OD63xtE5PiEQvF2=	M3TMeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373VR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXT2fmhKPyCm	M3zXR2ROW09?	MWfHTVUxRTJ6OD64xtE{OyEQvF2=	NH\yNFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
U87MG	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITUfnI4KGR?	MWfEUXNQ	MkO3S2k2OD1\|OD6zxtEzOCEQvF2=	M2j1UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
HCT116	M3riNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mnv5O{Bl	NWXHTm5vTE2VTx?=	MXXHTVUxRTV5OT65xtE{OiEQvF2=	NUHxclE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
DLD1	NEK0eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWO4fGd7PyCm	MXTEUXNQ	NGHDWVZIUTVyPUWwNU41yrF7MzFOwG0>	NHnCRXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
MRC5	NXriZpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXvkSmZYPyCm	NVnSVGVCTE2VTx?=	NWPMcopnT0l3ME20OFkvPMLzODFOwG0>	M{PQVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
SNB19V	M1S3T2Z2dmO2aX;uJGF{e2G7	NFS2dY0yODBizszNxsBVVVp?	MWqwMVczKGh?		MUTpcoNz\WG\|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=>	NIXlW\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
T98G	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojyOU8yOC9zNTFOwG0>	NYnqVnNWOjUEoHi=		MmPibY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS=	M1SzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[yPVYyLz5{NUK2Nlk3OTxxYU6=
U251	NVzTZXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorGOU8yOC9zNTFOwG0>	MXOyOOKhcA>?		NFGwd4VqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=>	MkCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
T98G	NWH1WVJmTnWwY4Tpc44hSXO\|YYm=	NX;3RZBQOTVizszN	NFHibIIzPMLiaB?=		NWmxZmREcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U251	MlHTSpVv[3Srb36gRZN{[Xl?	M{XwW\|E2KM7:TR?=	M3LK[\|I1yqCq		M1TGTYlv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?=	NVPIUpp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
U-87 MG	MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mom2O\|IhcA>?		MVnJR\|UxRTBwOUOgcW3DqA>?	NWr2[YdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U-118 MG	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnLXO\|IhcA>?		MYrJR\|UxRTFwMEWgcW3DqA>?	MmLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEWzN\|IoRjJ3MkS1N\|MzRC:jPh?=
U87	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVSyOEBp		M3\ITmlEPTB;Mk[wMlM1KM7:TdMg	MnL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzN{OyN\|MoRjJ3MUezNlM{RC:jPh?=
U87 GSLCs	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml7QNlQhcA>?		M2\yNWlEPTB;N{[2MlEyKM7:TdMg	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5M{KzN{c,OjVzN{OyN\|M9N2F-
U87MG	NF21[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlvoO\|IhcA>?		MoPuTWM2OD1zNT62NlUh\|ryPwrC=	MoniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUC5NVUoRjJ3MEWwPVE2RC:jPh?=
U251	NXPjOIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCxNFAuPDByIN88US=>	M2fZOVQ5KGh?	M3uzZ2ROW09?	M1fqSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
U87	NU\nVYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXixNFAuPDByIN88US=>	Ml;GOFghcA>?	M2m5[WROW09?	Mo\VbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MDA-MB-231-br	NXv2Wo1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPIS2FtOC1zMDFOwG0>	MUW0PEBp	M4nRZ2ROW09?	M2\MU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
HCC-1937	M3jtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFi5dWwxNTNyMDFOwG0>	M4nsWlQ5KGh?	MlSzSG1UVw>?	Ml\PbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3:1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
MDA-MB-231	M2nUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7I[oc5OC12MDFOwG0>	MkDROFghcA>?	NWHoWIZ4TE2VTx?=	NI\jdJFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
MDA-MB-468	NH\4S4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjMPVMxNTVyMDFOwG0>	M2jTflQ5KGh?	Mmn6SG1UVw>?	MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
T47D	NFvBZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHpZ\|IxNTFyMDFOwG0>	M{TsfFQ5KGh?	M4T1WWROW09?	NHjCO5lqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NYfHdWU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
MCF7	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36ydlAuOTByMDFOwG0>	MWe0PEBp	NI\oV2RFVVOR	NWfa[ZVLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MmezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
Hs683	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3faUlAuOTByMDFOwG0>	NVm1PWp6QTZiaB?=		NHf1OnRKSzVyPUGyPE46KM7:TR?=	M{LDOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
U87	NVm0[nBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrw[ZExNTFyMECg{txO	MnzQPVYhcA>?		NG[5VHpKSzVyPUG4MlQ2KM7:TR?=	M3LBVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
LNZ308	NXPncFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFT5dlYxNTFyMECg{txO	MXi5OkBp		MnHjTWM2OD1\|Mk[uO{DPxE1?	M33kWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
U87	MnTuRZBweHSxc3nzJGF{e2G7	M1XRblExOCEQvF2=	NFPRbIw1QCCq	MYrEUXNQ	NYHYfI9OcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=>	M1;5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEixOVg3Lz5{NES4NVU5PjxxYU6=
U251	M2rFTmFxd3C2b4Ppd{BCe3OjeR?=	M3nDe\|ExOCEQvF2=	MVu0PEBp	M2nOTWROW09?	NH;pO\|BqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5	NHrucnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4NVU5Pid-MkS0PFE2QDZ:L3G+
U251	NXHLPWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUSyOEBp		M1LPRmlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN	M{XFWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUC0PEBp		MYHJR\|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR\|Mk[5OVQ9N2F-
U251	M4OyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\rcIg4OiCq		MUjJR\|UxRTd{LkSy5qCKyrIkgJmxMlQ2KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR\|Mk[5OVQ9N2F-
U251	MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFK5NI06PiCq		M{DlRmlEPTB;NkmuPFLjiIoEsfMAjVMvODRizszN	Moe4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
T98G	M{TTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1T6XlAuPzVyIN88US=>	M2nLXVczNzl4IHi=		NIX6WXhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M3fIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0NFgxLz5{NEOyOFA5ODxxYU6=
U251-MG	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fzXFAuQDByIN88US=>	M{TCXVczKGh?		M2fsbIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NWWzTndIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM3OzBpPkK0NFk{PjNyPD;hQi=>
D54-MG	M1HmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfONE05ODBizszN	Mn3OO\|IhcA>?		NEjjc4FqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{[zNEc,OjRyOUO2N\|A9N2F-
SHG-44	NIXrXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nZfFExNTJyMDFOwG0>	NVewXGFkQTZiaB?=		MWnJR\|UxRTlwN{OgxtEhOi5zMjFOwG0>	M1zVVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[1OVY6Lz5{NEC2OVU3QTxxYU6=
U373	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPiWFNkOTBvMkCwJO69VQ>?	NVnZNYhGQTZiaB?=		Mkj1TWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>?	NY\0XoxsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlU2PjlpPkK0NFY2PTZ7PD;hQi=>
HT-29	M4LDc2Z2dmO2aX;uJGF{e2G7	M37p[\|UxOCEQvF2=	M2PHbFI1NzR6IHi=		NXfhSZpO\W6qYX7j[ZMhfGinIHzleoVteyCxZjFOt{1JOkG[wrC=	NVHyZ2xqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN\|gxPjhpPkK0NFM5ODZ6PD;hQi=>
PC-3	M4jSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqwMVI2KM7:TR?=	M1u5UVQ5KGh?		M3;0ZolvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>?	MnTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NE[5N\|QoRjJ\|N{S2PVM1RC:jPh?=
PC-3	NXvNW45YSXCxcITvd4l{KEG\|c3H5	MV2yOUDPxE1?	NFfDcY41QCCq		MlLybY5lfWOnczDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l	NUX4V2I6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFY6OzRpPkKzO\|Q3QTN2PD;hQi=>
T98G	M3fP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHrSGsyPTBvNECwJO69VQ>?	NELUSGwyPDRiaB?=		M4TYSIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M{fGbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{G1OFk6Lz5{M{exOVQ6QTxxYU6=
U87-MG	NILqZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xNFAhyrWP	Ml;oO\|IhcA>?		MnmybY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>?	NHfZb4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olc5QCd-MkO2PVY4QDh:L3G+
U251-MG	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;qZ5gyODBiwsXN	M3LSRlczKGh?		NE\ENFRqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE	MlnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OU[3PFgoRjJ\|Nkm2O\|g5RC:jPh?=
LNT-229	NIrWUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTJPZJ{Oy1zMECg{txO	NEHZWW0zPCCq		M2L0SolvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MoH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N\|IoRjJ\|Nk[3OlMzRC:jPh?=
T98G	NGn1V4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPZNVAuPzByIN88US=>	Mm\vNlQhcA>?		MVPpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{[zNkc,OjN4Nke2N\|I9N2F-
U87	NFjDWIJHfW6ldHnvckBCe3OjeR?=	NYG4UnNUOTByINM1US=>	M4\xWVMhcA>?		MljD[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob\|I>	NFLjfIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2O\|Q3QSd-MkO2Olc1Pjl:L3G+
HCT116	MV;GeY5kfGmxbjDBd5NigQ>?	NV\HeFczOTByINM1US=>	NUW2RXZKOyCq		NIjtSXRqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?=	MmXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke0OlkoRjJ\|Nk[3OFY6RC:jPh?=
HCT3-6	NF\4[mlHfW6ldHnvckBCe3OjeR?=	M{XaNVExOCEEtV2=	NYSy[4VrOyCq		MkP4bY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25?	NGL6V3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2O\|Q3QSd-MkO2Olc1Pjl:L3G+
U-87	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqwMVQxKM7:TR?=	NEXRXHIyOiCm		NXSxb2tKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87	NWfGb4QySXCxcITvd4l{KEG\|c3H5	MnzVNE01OCEQvF2=	MWWzM\|Yh\A>?		MWLpcoR2[2W\|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87	MUXGeY5kfGmxbjDBd5NigQ>?	NHLFTIMxNTRyIN88US=>	NG\PN3M{NzZiZB?=		NE[zPJZqdmS3Y3XzJIF2fG:yaHHnfUBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NIKyd3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OVczQSd-MkO2OFU4Ojl:L3G+
GB-SCC010	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1TzZ\|Qh\A>?		M3\ON2lEPTB;MkK2JO69VQ>?	M2HQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
GB-SCC026	NVLJWpg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYr4NGVoPCCm		NHu0WpNKSzVyPUWzMlEh\|ryP	M3POeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
GB-SCC028	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml7POEBl		M{XhbGlEPTB;MU[3JO69VQ>?	NX7Cd482RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
U87	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU[0JIQ>		NELKeYlKSzVyPUS1MlIh\|ryP	MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUK3OVUoRjJ\|NkGyO\|U2RC:jPh?=
U87 stem cell	M3i5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYLGNlhbPCCm		M4H6NmlEPTB;Nk[uO{DPxE1?	M2XaNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
TLX5 lymphoma	NGTYV5lEgXSxdH;4bYNqfHliYYPzZZk>				MWTJR\|UxKD1iNTFOwG0>	NWDpPXVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
GM892 A	MkXiR5l1d3SxeHnjbZR6KGG\|c3H5				Ml;xTWM2OCB;IEeuOkDPxE1?	NXrtUmp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
TLX5 lymphoma	M3HzOWN6fG:2b4jpZ4l1gSCjc4PhfS=>				M{nOVWlEPTBiPTC1JO69VQ>?	M1zHc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEW5NFE1Lz5zMkS1PVAyPDxxYU6=
HCT116	NYLwWmJkS3m2b4TvfIlkcXS7IHHzd4F6		MlTkOEBl[Xm\|		NWfXfndrUUN3MDC9JFQvOzRizszN	NUXmWFdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NFA5ODNpPkG5PFAxQDB\|PD;hQi=>
SNB75	M4PUNWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NGPBeFEyOCC3TR?=	MWKyOEBpenN?		NI\0bW5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPORlc2KGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDTVmIh[XO\|YYm=	NHG5W5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFUzPid-MkKyOlg2OjZ:L3G+
C6	MkXRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	M{HPVVExOCC3TR?=	NXTOeFVlPDhiaILz		MknQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDyZZQhSzZiY3XscJMh[XRiMUCwJJVOKGGodHXyJFQ5KGi{czDifUBv\XW2cnHsJJJm\CCrbnPvdpBwemG2aX;uJIF{e2G7	M3PKS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVI3Lz5{MkK2PFUzPjxxYU6=
SF295	NELRSHBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MmrRNVAhfU1?	M4PvSFI1KGi{cx?=		NVfuXGpWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTSlI6PSClZXzsd{BifCBzMDD1UUBi\nSncjCyOEBpenNiYomgV3JDKGG\|c3H5	MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1NlYoRjJ{Mk[4OVI3RC:jPh?=
U87	MoDQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWq1JIRigXN?		M4\VbWlEPTBiPTC0PUDPxE1?	M4ruZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkC4N\|g6Lz5{Mk[wPFM5QTxxYU6=
U138MG	NWLL[4JZS3m2b4TvfIlkcXS7IHHzd4F6		M{nFXlQ5KGi{cx?=		M1PLbWlEPTBiPTCyOkDPxE1?	M1Ox[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[5OlgzLz5{M{C2PVY5OjxxYU6=
C6	NX7RR4hxS3m2b4TvfIlkcXS7IHHzd4F6		NIX6Oo81QCCqcoO=		NIq4TYRKSzVyIE2gN\|Qh\|ryP	NHfhS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
A2780	NFzIc5dCdnSrdIXtc5Ih[XO\|YYm=		NHrncWQ2KGSjeYO=		MXvJR\|UxKD1iOD61JO69VQ>?	NHWzNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5OVYzOCd-MkO4PVU3OjB:L3G+
A2058	MkjERY51cXS3bX;yJIF{e2G7		NFzF[4M2KGSjeYO=		NYrobGx6UUN3MDC9JFM2NjVizszN	NGDpdIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5OVYzOCd-MkO4PVU3OjB:L3G+
SNB19	NI\4dZRCdnSrdIXtc5Ih[XO\|YYm=		MoDHOUBl[Xm\|		NXHybm9NUUN3MDC9JFM4KM7:TR?=	NYHkcW9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4PVU3OjBpPkKzPFk2PjJyPD;hQi=>
M8	NEXkXIlCeG:ydH;zbZMh[XO\|YYm=	NUHLSWJxPTBidH:gNVAxKHWP	MkDvOFghcHK\|		NIX5XHdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF24JINmdGy\|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEA2OCC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KEGSQz3sZYJmdGWmIHHucoV5cW5iVjDhcoQhPy2DQVSgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{	NEXKV3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
SK-MEL-30	MX7BdI9xfG:\|aYOgZZN{[Xl?	M4rBV\|ExOCC3TR?=	MmnrOFghcHK\|		MUXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFONLV3FUE0{OCClZXzsd{Bie3Onc4Pl[EBieyCjcH;weI91cWNxbnXjdo91cWNiY3XscJMh[XRiMUCwJJVOKGGodHXyJFQ5KGi{czDifUBCWENvbHHi[Yxm\CCjbn7lfIlvKFZiYX7kJFcuSUGGIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{Bz\WyjdHn2[UB1dyClb370do9t	M3naUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK1PFc4Lz5{NEGyOVg4PzxxYU6=
SK-MEL-30	NYPoUJJxSXCxcITvd4l{KGG\|c3H5	M2KwT\|UxKHWP	MnXzOFghcHK\|		M3XiTGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iU1utUWVNNTNyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHwc5B1d3SrYz;u[YNzd3SrYzDj[YxteyCjdDC1NEB2VSCjZoTldkA1QCCqcoOgZpkhSVCFLXzhZoVt\WRiYX7u[ZhqdiCYIHHu[EA4NUGDRDDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMhemWuYYTpeoUhfG9iY3;ueJJwdA>?	NYPZbnZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlU5PzdpPkK0NVI2QDd5PD;hQi=>
MNT1	MVzBdI9xfG:\|aYOgZZN{[Xl?	M33CO\|ExOCC3TR?=	MnK2OFghcHK\|		NYXFU3kyUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNUnQyKGOnbHzzJIF{e2W\|c3XkJIF{KGGyb4D0c5Rq[y:wZXPyc5Rq[yClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK\|IHL5JGFRSy2uYXLlcIVlKGGwbnX4bY4hXiCjbnSgO{1CSURic4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w>	NIi4TYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1	M{C2WWFxd3C2b4Ppd{Bie3OjeR?=	MkPIOVAhfU1?	MnXROFghcHK\|		MlTITY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPTmSxJINmdGy\|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEA2OCC3TTDh[pRmeiB2ODDodpMh[nliQWDDMYxi[mWuZXSgZY5v\XirbjDWJIFv\CB5LVHBSEB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MkfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O\|coRjJ2MUK1PFc4RC:jPh?=
A2780	NUnPTYw6S3m2b4TvfIlkcXS7IHHzd4F6		MmP5OUBl[Xm\|		MofBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JG1VXCCjc4PhfS=>	NGH6Xpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFQyQCd-MkS5NFA1OTh:L3G+
A2780/CP70	NVrxb5dLS3m2b4TvfIlkcXS7IHHzd4F6		M3rONlUh\GG7cx?=		NILLeJhEgXSxdH;4bYNqfHliYXfhbY5{fCCPTWKt[IVncWOrZX70JIh2dWGwIFGyO\|gxN0OSN{CgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigQ>?	NGPEZW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFQyQCd-MkS5NFA1OTh:L3G+
GBM 047T	M{\uemFvfGm2dX3vdkBie3OjeR?=	MmnHNlAhfU1?	NHLyUpcyKHSxIEKge4Vmc3N?		NFLyeFFVfW2xcnnjbYRidCCnZn\lZ5QhcW5icHH0bYVvfCCmZYLpeoVlKEeETTCwOFdVKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDu[ZVzd3OyaHXy[UBnd3KvYYTpc44h[XRiMkCgeW0h[W[2ZYKgNUB1dyB{IIfl[Yt{KGK7IEPEJJR2dW:{IHPsc45w\2WwaXOgZZN{[Xl?	MlvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUW1N\|IoRjJ4M{W1OVMzRC:jPh?=
GBM 464T	M1Thb2FvfGm2dX3vdkBie3OjeR?=	NGCycpYzOCC3TR?=	NIL2XY0yKHSxIEKge4Vmc3N?		NWXHeFZSXHWvb4LpZ4ll[WxiZX\m[YN1KGmwIIDheIlmdnRiZHXybZZm\CCJQl2gOFY1XCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gcoV2em:\|cHjldoUh\m:{bXH0bY9vKGG2IEKwJJVOKGGodHXyJFEhfG9iMjD3[YVseyCkeTCzSEB1fW2xcjDjcI9vd2enbnnjJIF{e2G7	NXG5c\|N5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVU2OzJpPkK2N\|U2PTN{PD;hQi=>
U87MG	M3jBSmZ2dmO2aX;uJIF{e2G7		Mo\WN{BpenN?		MVTJcoR2[3Srb36gc4YhTE6DIHHsb5lt[XSrb36gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gUlcuVWWmRzDmc5Ju[XSrb36gZYZ1\XJiMzDodpMh[nliTFOtUXMwVVNiYX7hcJl{cXN?	M4jqU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkG0OFE1Lz5{N{[xOFQyPDxxYU6=
U87MG	NXL6PFFQSW62aYT1cY9zKGG\|c3H5				M{SxeWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJI9zfGixdH;wbYNidGy7IIjlco9oemGodHXkJIlvKEijcnzhckBvfWSnIH3veZNmKGK{YXnuJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDzcI94KHS3bX;yJIdzd3e2aDDheEA2OCC3bX;sM4toNCCrdjDh[I1qdmm\|dHXy[YQhd26lZTDkZYltgSCob4KgOUBl[Xm\|	M13zTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkG0OFE1Lz5{N{[xOFQyPDxxYU6=
U87MG	NFW3cXlCdnSrdIXtc5Ih[XO\|YYm=				NUTqdJpJSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gWVg4VUdiY3XscJMhd3K2aH;0c5Bq[2GubImgfIVvd2e{YX\0[YQhcW5iSHHycIFvKG63ZHWgcY92e2ViYoLhbY4h[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gcY92e2Vic4Xyeol3[WxiYYSgOVAhfW2xbD;r[{whcXZiYXTtbY5qe3SncnXkJI9v[2ViZHHpcJkh\m:{IEWg[IF6ew>?	NWHrV2JtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
MDCK	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		MXWyOEBpenN?		NGjQPXVEgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy\|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG\|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{M{i3PUc,Ojd6MkO4O\|k9N2F-
MDCK	NInrNmNEgXSxdH;4bYNqfHliYYPzZZk>		MYSyOEBpenN?		MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBOTEONIHPlcIx{KGW6cILld5NqdmdiY3HyZo9vcWNiYX7ofYRz[XOnIEmgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgNlQhcHK\|IH3lZZN2emWmIHHmeIVzKDdiZHH5d{B2dmSncjDofZBwgGmlIHPvcoRqfGmxbjDifUBu\XSqeXzlcoUh[my3ZTDzeIFqdmmwZzDiZZNm\CClbH;uc4dmdmmlIIP1dpZqfmGuIHHzd4F6	M{Dn[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEKzPFc6Lz5{N{iyN\|g4QTxxYU6=
NB-EBc1	MlvQdWhVWyCjc4PhfS=>				MmnMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M2nBZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
C6	NUDQfXo2S3m2b4TvfIlkcXS7IHHzd4F6		M3HUXlQh\GG7cx?=		NYiyO3JrTUN3MDC9JFE3NjVizszN	NYfqb4pmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
U87	NXjW[WdUS3m2b4TvfIlkcXS7IHHzd4F6		NXTYZmZkPzJiaILz		NF;Eb\|JKSzVyIE2gNVkvOzhizszN	M3r4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
SNB19	MlK1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWK3JIRigXN?		M{LBTGdKPTBiPTCzOU44KM7:TR?=	NGHIe\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
SNB19	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEL1UmM4KGSjeYO=		M4XSPWdKPTBiPTC0OU43KM7:TR?=	NUe1OY1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
U373	NUDvdIlITnWwY4Tpc44h[XO\|YYm=	NXLHTW1JOTByIIXN	NYjkPG5yPzJiaILz		M1XpcGlv\HWldHnvckBw\iCmb4XicIUhe3S{YX7k[YQhTE6DIHLy[YFsKGmwIHXtdJR6KH[nY4TvdkB1emGwc3\lZ5Rm\CCqdX3hckBWOzd\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIdidW2jLViyRXghdGW4ZXygZZQhOTByIIXNJIFnfGW{IEeyJIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>?	M1i1SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
Glioma	NUPkSVBUSW62aYT1cY9zKGG\|c3H5				M1PRXWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGhwdW9ic3HwbYVveyBqaIXtZY4qKEeuaX;tZUBk\WyuczD4[Y5w\3KjZoTl[EBqdiC2cnHud4dmdmmlIH3veZNmKGG\|c3Xzd4VlKGG\|IH3veZNmKHO3co\peoFt	NXfvNm8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID

Western blot	pERK / ERK / p-p38 / p38 ; DR5 / c-FLIP / Survivin / XIAP	24436439
Growth inhibition assay	Cell viability	25751281
Immunofluorescence	Phalloidin / Phospho-H2A.X ; cleaved caspase-3	27375225 25663820

体内試験

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. ^[1]

お薦めの試験操作（参考用のみ）

細胞試験： ^[1]	細胞株：L-1210 and L-1210/BCNU cells 濃度： 0 μM -100 μM 反応時間：l hours 実験の流れ： L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.
動物試験： ^[1]	動物モデル：DBA/2 mice with L-1210 and L-1210/BCNU cells 投薬量：40 mg/kg 投与方法：Administered via i.v.

細胞試験：

^[1]

細胞株：L-1210 and L-1210/BCNU cells
濃度： 0 μM -100 μM
反応時間：l hours
実験の流れ：
L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.

動物試験：

^[1]

動物モデル：DBA/2 mice with L-1210 and L-1210/BCNU cells
投薬量：40 mg/kg
投与方法：Administered via i.v.

参考	[1] Catapano CV, et al. Cancer Res. 1987, 47(18), 4884-4889. [2] Sun S, et al. J Neurooncol. 2012. [3] Bauer M, et al. PLoS One. 2012, 7(6):e39956. [4] Wong ST, et al. Anticancer Res. 2012, 32(7), 2835-2841. [5] Lin CJ, et al. PLoS One. 2012, 7(6), e38706. [6] Gori JL, et al. Cancer Gene Ther. 2012. + 展開

参考

+ 展開

溶解度 (25°C)

体外


体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+30% PEG 300+ddH2O 混合させたのち直ちに使用することを推奨します。注文はこちらから: PEG300	2mg/mL

化学情報

分子量	194.15
化学式	C₆H₆N₆O₂
CAS No.	85622-93-1
Storage	3年	-20°C	粉
Storage	2年	-80°C	in solvent
Smiles	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

Temozolomide (CCRG 81045) SDFをダウンロードする

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

臨床試験

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05128734	Not yet recruiting	Drug: Temozolomide\|Drug: Olaparib	Breast Cancer Triple Negative	AHS Cancer Control Alberta	December 1 2022	Phase 2
NCT04200066	Not yet recruiting	Drug: Temozolomide Tamoxifen Maprotiline	Glioblastoma\|Brain Tumor	University of Rochester	June 1 2022	Phase 1
NCT03796507	Withdrawn	Drug: Temozolomide	Glioma of Brain	University of Rochester\|National Institutes of Health (NIH)	September 1 2021	Early Phase 1
NCT04901702	Recruiting	Drug: Onivyde\|Drug: Talazoparib\|Drug: Temozolomide	Recurrent Solid Tumor\|Recurrent Ewing Sarcoma\|Recurrent Hepatoblastoma\|Recurrent Malignant Germ Cell Tumor\|Recurrent Malignant Solid Neoplasm\|Recurrent Neuroblastoma\|Recurrent Osteosarcoma\|Recurrent Peripheral Primitive Neuroectodermal Tumor\|Recurrent Rhabdoid Tumor\|Recurrent Rhabdomyosarcoma\|Recurrent Soft Tissue Sarcoma\|Recurrent Wilms Tumor\|Refractory Ewing Sarcoma\|Refractory Hepatoblastoma\|Refractory Malignant Germ Cell Tumor\|Refractory Malignant Solid Neoplasm\|Refractory Neuroblastoma\|Refractory Osteosarcoma\|Refractory Peripheral Primitive Neuroectodermal Tumor\|Refractory Rhabdoid Tumor\|Refractory Rhabdomyosarcoma\|Refractory Soft Tissue Sarcoma	St. Jude Children''s Research Hospital\|Pfizer\|Ipsen	June 9 2021	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):